[go: up one dir, main page]

AR106487A1 - Antagonistas de receptores de cgrp - Google Patents

Antagonistas de receptores de cgrp

Info

Publication number
AR106487A1
AR106487A1 ARP160103294A ARP160103294A AR106487A1 AR 106487 A1 AR106487 A1 AR 106487A1 AR P160103294 A ARP160103294 A AR P160103294A AR P160103294 A ARP160103294 A AR P160103294A AR 106487 A1 AR106487 A1 AR 106487A1
Authority
AR
Argentina
Prior art keywords
cgrp
receiver antagonists
antagonists
cgrp receiver
cerebrovascular
Prior art date
Application number
ARP160103294A
Other languages
English (en)
Inventor
Stephen Mason Jonathan
Pickworth Mark
Deflorian Francesca
Joanne Bucknell Sarah
Stuart Congreve Miles
Andrew Christopher John
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of AR106487A1 publication Critical patent/AR106487A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Su uso en el tratamiento, la prevención el mejoramiento, el control o la reducción de trastornos cerebrovasculares o vasculares asociados con la función del receptor del CGRP. Reivindicación 1: Un compuesto de la fórmula (1), o las sales del mismo, en donde R¹ es H o F y Ar¹ es un anillo heterocíclico de 5 miembros opcionalmente sustituido que contiene por lo menos dos átomos de nitrógeno.
ARP160103294A 2015-10-30 2016-10-28 Antagonistas de receptores de cgrp AR106487A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1519194.3A GB201519194D0 (en) 2015-10-30 2015-10-30 CGRP receptor antagonists

Publications (1)

Publication Number Publication Date
AR106487A1 true AR106487A1 (es) 2018-01-17

Family

ID=55130446

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103294A AR106487A1 (es) 2015-10-30 2016-10-28 Antagonistas de receptores de cgrp

Country Status (13)

Country Link
US (3) US9688660B2 (es)
EP (1) EP3368526B1 (es)
JP (1) JP6874014B2 (es)
CN (1) CN108430991B (es)
AR (1) AR106487A1 (es)
AU (1) AU2016344689A1 (es)
BR (1) BR112018008416A2 (es)
CA (1) CA3002625A1 (es)
GB (1) GB201519194D0 (es)
IL (1) IL258894A (es)
SG (1) SG11201803382XA (es)
TW (1) TW201722936A (es)
WO (1) WO2017072723A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
EP4076395A4 (en) * 2019-12-17 2024-02-07 Pfizer Ireland Pharmaceuticals INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS
WO2024046223A1 (zh) * 2022-08-30 2024-03-07 熙源安健医药（上海）有限公司 吲唑甲酰胺类衍生物及其制备方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
ATE266673T1 (de) 1996-09-10 2004-05-15 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
CA2334551A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
DE19952146A1 (de) * 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
PT1539766T (pt) 2002-06-05 2017-03-02 Bristol Myers Squibb Co Antagonistas de recetor de péptido relacionado com o gene de calcitonina
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
CA2549330A1 (en) 2003-12-05 2005-07-21 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050233980A1 (en) * 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
KR20070062997A (ko) 2004-10-13 2007-06-18 머크 앤드 캄파니 인코포레이티드 Ｃｇｒｐ 수용체 길항제
JP2008516957A (ja) 2004-10-14 2008-05-22 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
CN101068595A (zh) 2004-10-22 2007-11-07 默克公司 Cgrp受体拮抗剂
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
EP2029234A1 (en) 2006-06-08 2009-03-04 Boehringer Ingelheim International GmbH Treatment of gastrointestinal disorders with cgrp-antagonists
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
EA020548B1 (ru) * 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8481546B2 (en) * 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists

Also Published As

Publication number Publication date
JP6874014B2 (ja) 2021-05-19
TW201722936A (zh) 2017-07-01
US10166226B2 (en) 2019-01-01
CN108430991B (zh) 2021-01-05
WO2017072723A1 (en) 2017-05-04
US20170121311A1 (en) 2017-05-04
EP3368526B1 (en) 2019-12-25
US20180153876A1 (en) 2018-06-07
BR112018008416A2 (pt) 2018-10-23
EP3368526A1 (en) 2018-09-05
IL258894A (en) 2018-06-28
CN108430991A (zh) 2018-08-21
GB201519194D0 (en) 2015-12-16
US20170239236A1 (en) 2017-08-24
SG11201803382XA (en) 2018-05-30
CA3002625A1 (en) 2017-05-04
US9688660B2 (en) 2017-06-27
AU2016344689A1 (en) 2018-05-17
US9925178B2 (en) 2018-03-27
JP2018532790A (ja) 2018-11-08

Similar Documents

Publication Publication Date Title
JOP20200209A1 (ar) مثبطات cd73
UY36684A (es) Agonistas de triazol del receptor apj
SV2018005723A (es) Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos
BR112018008423A2 (pt) antagonistas do receptor cgrp
AR106487A1 (es) Antagonistas de receptores de cgrp
IL271266A (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
AR106488A1 (es) Antagonistas de receptores de cgrp
LT3805220T (lt) Policikliniai karbamoilpiridono dariniai, skirti živ gydymui
EP3810614C0 (en) BRIDGED COMPOUNDS FOR USE AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS
EP4034156A4 (en) COMBINATION THERAPY WITH CGRP ANTAGONISTS
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона
MX2020003507A (es) Compuestos pirimidinicos inhibidores de (tbk)/(ikk) epsilon y usos de los mismos.
PH12018500282A1 (en) Cgrp receptor antagonists
EP3506925C0 (en) USE OF CGRP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GLAUCOMA
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
AR111665A1 (es) Derivados de 3-metil-pirrolidina-2,5-diona útiles como antagonistas del receptor cgrp
CL2017002163A1 (es) Derivado de imidazopirimidina e imidazotriazina, y composición farmacéutica que lo comprende.
PH12017501214A1 (en) Cgrp antagonist peptides
UY37339A (es) Formas de sal de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1himidazol-2-carboxamida y composiciones que las contienen
EA033085B1 (ru) Производные 2-(1-гетероарилпиперазин-4-ил)метил-1,4- бензодиоксана в качестве альфа2c-антагонистов
MX2019001696A (es) Combinacion de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa.
EP3429588A4 (en) AMID SULPHAMIDE DERIVATIVES, COMPOSITIONS AND USES ASSOCIATED WITH CXCR4 INHIBITION
CL2018001871A1 (es) Uso de inhibidores de la actividad o función de pi3k para el tratamiento del síndrome de sjögren primario

Legal Events

Date Code Title Description
FB Suspension of granting procedure